Method for treating blood, blood products and organs

Patent metadata

Field	Value
Publication number	US-9591845-B2
Application number	US-201314388865-A
Country	US
Kind code	B2
Filing date	Apr 5, 2013
Priority date	Apr 5, 2012
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

First claim

What is claimed is:

1. A method for treating blood, a blood product and/or an organ in vitro or ex vivo, wherein the method comprises removing the blood, blood product and/or organ from the human or animal body and removing and/or detoxifying amyloid-beta oligomers from the removed blood, blood product and/or organ, and wherein the method comprises contacting the blood, blood product and/or organ with one or more compounds which comprise the compound rprtrlrthqnr (DB 4:SEQ ID NO:1).

2. The method of claim 1 , wherein the method further comprises examining the blood, blood product and/or organ for the presence of amyloid-beta oligomers prior to removing the blood, blood product and/or organ from the human or animal body.

3. The method of claim 1 , wherein the one or more compounds are arranged as capture molecules on a support, via which a sample containing the blood, blood product and/or organ is passed.

4. The method of claim 3 , wherein the capture molecules are fixed onto beads.

5. The method of claim 3 , wherein the capture molecules are immobilized on nanomagnets.

6. The method of claim 3 , wherein the capture molecules are arranged in a dialysis system.

7. The method of claim 3 , wherein the support for the capture molecules is made of a biocompatible material.

8. The method of claim 3 , wherein the support for the capture molecules is selected from one or more of membranes, filters, filter sponges, beads, rods, cords, column, hollow fibers.

9. The method of claim 1 , wherein a kit is used for a selective quantification of A-beta aggregates and/or for treating (in vitro) blood, a blood product and/or an organ, the kit comprising one or more of:
a substrate made of glass which is coated with a hydrophobic material;
a standard;
a capture molecule;
a probe;
a substrate with capture molecule;
one or more solutions;
a buffer.

10. The method of claim 1 , wherein the one or more compounds are passed as capture molecules ex vivo over and/or through an organ.

11. The method of claim 1 , wherein the method comprises removing amyloid-beta oligomers from blood, a blood product and/or an organ.

12. The method of claim 11 , wherein Alzheimer's disease is treated.

13. The method of claim 1 , wherein the method comprises detoxifying amyloid-beta oligomers present in blood, a blood product and/or an organ.

14. The method of claim 13 , wherein Alzheimer's disease is treated.

15. The method of claim 1 , wherein the one or more compounds further comprise one or more hybrid compounds of formula A-B, where A is an aminopyrazole or a derivative thereof, and B is a peptide selected from SEQ ID NO:1, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76,
and A and B are covalently bonded to one another directly or by a linker.

Assignees

• Forschungszentrum Juelich Gmbh

Inventors

• Willbold Dieter

Classifications

• A61P39/02

  Antidotes · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title